{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:36:49Z","timestamp":1793320609616,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The concept of liquid biopsy analysis has been established more than a decade ago. Since the establishment of the term, tremendous advances have been achieved and plenty of methods as well as analytes have been investigated in basic research as well in clinical trials. Liquid biopsy refers to a body fluid-based biopsy that is minimal-invasive, and most importantly, allows dense monitoring of tumor responses by sequential blood sampling. Blood is the most important analyte for liquid biopsy analyses, providing an easily accessible source for a plethora of cells, cell-derived products, free nucleic acids, proteins as well as vesicles. More than 12,000 publications are listed in PubMed as of today including the term liquid biopsy. In this manuscript, we critically review the current implications of liquid biopsy, with special focus on circulating tumor cells, and describe the hurdles that need to be addressed before liquid biopsy can be implemented in clinical standard of care guidelines.<\/jats:p>","DOI":"10.1007\/s10585-024-10267-5","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T11:01:46Z","timestamp":1706439706000},"page":"403-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinical applications of circulating tumor cells in patients with solid tumors"],"prefix":"10.1007","volume":"41","author":[{"given":"Daniel J.","family":"Smit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Schneegans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,28]]},"reference":[{"issue":"1","key":"10267_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J et al (2020) Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 5(1):28","journal-title":"Signal Transduct Target Ther"},{"issue":"7586","key":"10267_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature17038","volume":"529","author":"J Massagu\u00e9","year":"2016","unstructured":"Massagu\u00e9 J, Obenauf AC (2016) Metastatic colonization by circulating tumour cells. Nature 529(7586):298\u2013306","journal-title":"Nature"},{"issue":"5","key":"10267_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871\u2013890","journal-title":"Cell"},{"issue":"1","key":"10267_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto MA et al (2016) EMT: 2016. Cell 166(1):21\u201345","journal-title":"Cell"},{"issue":"1","key":"10267_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.trecan.2015.07.009","volume":"1","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Massagu\u00e9 J (2015) Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer 1(1):76\u201391","journal-title":"Trends Cancer"},{"key":"10267_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcancer.2021.02.001","volume":"78","author":"S Werner","year":"2022","unstructured":"Werner S, Heidrich I, Pantel K (2022) Clinical management and biology of tumor dormancy in breast cancer. Semin Cancer Biol 78:49\u201362","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"10267_CR7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41571-021-00499-9","volume":"18","author":"LC Hofbauer","year":"2021","unstructured":"Hofbauer LC et al (2021) Novel approaches to target the microenvironment of bone metastasis. Nat Rev Clin Oncol 18(8):488\u2013505","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10267_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMoa050434","volume":"353","author":"S Braun","year":"2005","unstructured":"Braun S et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793\u2013802","journal-title":"N Engl J Med"},{"key":"10267_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.semcancer.2019.09.002","volume":"60","author":"O Hen","year":"2020","unstructured":"Hen O, Barkan D (2020) Dormant disseminated tumor cells and cancer stem\/progenitor-like cells: similarities and opportunities. Sem Cancer Biol 60:157\u2013165","journal-title":"Sem Cancer Biol"},{"issue":"1","key":"10267_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/1878-0261.12022","volume":"11","author":"A Dasgupta","year":"2017","unstructured":"Dasgupta A, Lim AR, Ghajar CM (2017) Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol 11(1):40\u201361","journal-title":"Mol Oncol"},{"issue":"17","key":"10267_CR11","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/jnci\/85.17.1419","volume":"85","author":"K Pantel","year":"1993","unstructured":"Pantel K et al (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85(17):1419\u20131424","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10267_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/gcc.22695","volume":"58","author":"E Lianidou","year":"2019","unstructured":"Lianidou E, Pantel K (2019) Liquid biopsies. Genes Chromosomes Cancer 58(4):219\u2013232","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10267_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ccell.2015.10.007","volume":"28","author":"SA Joosse","year":"2015","unstructured":"Joosse SA, Pantel K (2015) Tumor-educated platelets as Liquid Biopsy in Cancer patients. Cancer Cell 28(5):552\u2013554","journal-title":"Cancer Cell"},{"issue":"10","key":"10267_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","volume":"19","author":"L Keller","year":"2019","unstructured":"Keller L, Pantel K (2019) Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer 19(10):553\u2013567","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"10267_CR15","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1158\/1078-0432.CCR-04-1110","volume":"10","author":"S Meng","year":"2004","unstructured":"Meng S et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10(24):8152\u20138162","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10267_CR16","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3390\/cancers5041619","volume":"5","author":"AM Barradas","year":"2013","unstructured":"Barradas AM, Terstappen LW (2013) Towards the Biological understanding of CTC: capture technologies, definitions and potential to create metastasis. Cancers (Basel) 5(4):1619\u20131642","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10267_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabieres","year":"2021","unstructured":"Alix-Panabieres C, Pantel K (2021) Liquid Biopsy: from Discovery to Clinical Application. Cancer Discov 11(4):858\u2013873","journal-title":"Cancer Discov"},{"issue":"17","key":"10267_CR18","doi-asserted-by":"publisher","first-page":"24677","DOI":"10.18632\/oncotarget.8250","volume":"7","author":"KA Hyun","year":"2016","unstructured":"Hyun KA et al (2016) Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget 7(17):24677\u201324687","journal-title":"Oncotarget"},{"key":"10267_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-642-28160-0_6","volume":"195","author":"C Alix-Panabieres","year":"2012","unstructured":"Alix-Panabieres C (2012) EPISPOT assay: detection of viable DTCs\/CTCs in solid tumor patients. Recent Results Cancer Res 195:69\u201376","journal-title":"Recent Results Cancer Res"},{"issue":"7","key":"10267_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabieres C (2019) Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol 16(7):409\u2013424","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10267_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s41416-022-01819-1","volume":"127","author":"Z Eslami-S","year":"2022","unstructured":"Eslami-S Z et al (2022) Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade. Br J Cancer 127(5):800\u2013810","journal-title":"Br J Cancer"},{"issue":"4","key":"10267_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1373\/clinchem.2018.296814","volume":"65","author":"A Franken","year":"2019","unstructured":"Franken A et al (2019) Label-Free Enrichment and Molecular characterization of viable circulating tumor cells from Diagnostic Leukapheresis products. Clin Chem 65(4):549\u2013558","journal-title":"Clin Chem"},{"issue":"5","key":"10267_CR23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3390\/jpm12050666","volume":"12","author":"Y Shimada","year":"2022","unstructured":"Shimada Y et al (2022) Cell lines of circulating Tumor cells: what is known and what needs to be resolved. J Personalized Med 12(5):666","journal-title":"J Personalized Med"},{"issue":"10","key":"10267_CR24","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/cells8101145","volume":"8","author":"T Tayoun","year":"2019","unstructured":"Tayoun T et al (2019) CTC-derived models: a window into the seeding capacity of circulating tumor cells (CTCs). Cells 8(10):1145","journal-title":"Cells"},{"issue":"5","key":"10267_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1158\/0008-5472.CAN-14-2613","volume":"75","author":"L Cayrefourcq","year":"2015","unstructured":"Cayrefourcq L et al (2015) Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 75(5):892\u2013901","journal-title":"Cancer Res"},{"issue":"1","key":"10267_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41598-019-57164-6","volume":"10","author":"D Brungs","year":"2020","unstructured":"Brungs D et al (2020) Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer. Sci Rep 10(1):539","journal-title":"Sci Rep"},{"key":"10267_CR27","doi-asserted-by":"publisher","first-page":"114589","DOI":"10.1016\/j.bcp.2021.114589","volume":"188","author":"DJ Smit","year":"2021","unstructured":"Smit DJ, Pantel K, J\u00fccker M (2021) Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy. Biochem Pharmacol 188:114589","journal-title":"Biochem Pharmacol"},{"key":"10267_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2021.03.023","volume":"150","author":"L Mout","year":"2021","unstructured":"Mout L et al (2021) Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. Eur J Cancer 150:179\u2013189","journal-title":"Eur J Cancer"},{"key":"10267_CR29","doi-asserted-by":"crossref","unstructured":"Smit DJ et al (2020) High sensitivity of circulating Tumor cells derived from a colorectal Cancer patient for dual inhibition with AKT and mTOR inhibitors. Cells, 9(9)","DOI":"10.3390\/cells9092129"},{"issue":"9","key":"10267_CR30","doi-asserted-by":"publisher","first-page":"e11908","DOI":"10.15252\/emmm.201911908","volume":"12","author":"C Koch","year":"2020","unstructured":"Koch C et al (2020) Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol Med 12(9):e11908","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10267_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12935-019-0735-z","volume":"19","author":"Z Que","year":"2019","unstructured":"Que Z et al (2019) Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo. Cancer Cell Int 19(1):21","journal-title":"Cancer Cell Int"},{"issue":"6193","key":"10267_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1126\/science.1253533","volume":"345","author":"M Yu","year":"2014","unstructured":"Yu M et al (2014) Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345(6193):216\u2013220","journal-title":"Science"},{"issue":"8","key":"10267_CR33","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nm.3600","volume":"20","author":"CL Hodgkinson","year":"2014","unstructured":"Hodgkinson CL et al (2014) Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 20(8):897\u2013903","journal-title":"Nat Med"},{"issue":"1","key":"10267_CR34","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1038\/s41467-020-15426-2","volume":"11","author":"V Faugeroux","year":"2020","unstructured":"Faugeroux V et al (2020) Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model. Nat Commun 11(1):1884","journal-title":"Nat Commun"},{"issue":"6","key":"10267_CR35","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/jnci\/djy018","volume":"110","author":"FC Bidard","year":"2018","unstructured":"Bidard FC et al (2018) Circulating Tumor cells in breast Cancer patients treated by Neoadjuvant Chemotherapy: a Meta-analysis. J Natl Cancer Inst 110(6):560\u2013567","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10267_CR36","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1158\/1078-0432.CCR-18-0120","volume":"24","author":"KE Effenberger","year":"2018","unstructured":"Effenberger KE et al (2018) Improved risk stratification by circulating Tumor Cell counts in Pancreatic Cancer. Clin Cancer Res 24(12):2844\u20132850","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10267_CR37","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1097\/SLA.0000000000001130","volume":"261","author":"M Reeh","year":"2015","unstructured":"Reeh M et al (2015) Circulating Tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal Cancer. Ann Surg 261(6):1124\u20131130","journal-title":"Ann Surg"},{"key":"10267_CR38","doi-asserted-by":"crossref","unstructured":"Rack B et al (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst, 106(5)","DOI":"10.1093\/jnci\/dju066"},{"issue":"18","key":"10267_CR39","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-17-0255","volume":"23","author":"S Riethdorf","year":"2017","unstructured":"Riethdorf S et al (2017) Prognostic impact of circulating Tumor cells for breast Cancer patients treated in the Neoadjuvant Geparquattro Trial. Clin Cancer Res 23(18):5384\u20135393","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10267_CR40","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/jnci\/djy152","volume":"111","author":"E Trapp","year":"2019","unstructured":"Trapp E et al (2019) Presence of circulating Tumor cells in high-risk early breast Cancer during Follow-Up and Prognosis. J Natl Cancer Inst 111(4):380\u2013387","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10267_CR41","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1001\/jamaoncol.2018.2574","volume":"4","author":"J Sparano","year":"2018","unstructured":"Sparano J et al (2018) Association of circulating Tumor cells with late recurrence of Estrogen receptor\u2013positive breast Cancer: a secondary analysis of a Randomized Clinical Trial. JAMA Oncol 4(12):1700\u20131706","journal-title":"JAMA Oncol"},{"issue":"20","key":"10267_CR42","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-12-1587","volume":"18","author":"L Zhang","year":"2012","unstructured":"Zhang L et al (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18(20):5701\u20135710","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10267_CR43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41571-023-00781-y","volume":"20","author":"R Lawrence","year":"2023","unstructured":"Lawrence R et al (2023) Circulating tumour cells for early detection of clinically relevant cancer. Nat Reviews Clin Oncol 20(7):487\u2013500","journal-title":"Nat Reviews Clin Oncol"},{"key":"10267_CR44","doi-asserted-by":"crossref","unstructured":"Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program\u2009<\u2009sup>\u2606 ESMO Open, 2021. 6(6)","DOI":"10.1016\/j.esmoop.2021.100299"},{"issue":"6","key":"10267_CR45","doi-asserted-by":"publisher","first-page":"e0123683","DOI":"10.1371\/journal.pone.0123683","volume":"10","author":"S Agelaki","year":"2015","unstructured":"Agelaki S et al (2015) Efficacy of Lapatinib in Therapy-resistant HER2-Positive circulating tumor cells in metastatic breast Cancer. PLoS ONE 10(6):e0123683","journal-title":"PLoS ONE"},{"issue":"4Supplement","key":"10267_CR46","first-page":"PD3","volume":"81","author":"T Fehm","year":"2021","unstructured":"Fehm T et al (2021) Abstract PD3-12: efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial. Cancer Res 81(4Supplement):PD3\u201312","journal-title":"Cancer Res"},{"key":"10267_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00023","volume":"1","author":"A De Gregorio","year":"2017","unstructured":"De Gregorio A et al (2017) Discordance in human epidermal growth factor receptor 2 (HER2) phenotype between primary tumor and circulating Tumor cells in women with HER2-Negative metastatic breast Cancer. JCO Precis Oncol 1:1\u201312","journal-title":"JCO Precis Oncol"},{"key":"10267_CR48","doi-asserted-by":"publisher","first-page":"p1718920","DOI":"10.1155\/2019\/1718920","volume":"2019","author":"C Nicolazzo","year":"2019","unstructured":"Nicolazzo C et al (2019) EpCAM(low) circulating Tumor cells: gold in the Waste. Dis Markers 2019:p1718920","journal-title":"Dis Markers"},{"issue":"12","key":"10267_CR49","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/cyto.a.23669","volume":"93","author":"TN Fehm","year":"2018","unstructured":"Fehm TN et al (2018) Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting. Cytometry A 93(12):1213\u20131219","journal-title":"Cytometry A"},{"issue":"5","key":"10267_CR50","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/1878-0261.13415","volume":"17","author":"M Abdo","year":"2023","unstructured":"Abdo M et al (2023) Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients. Mol Oncol 17(5):737\u2013746","journal-title":"Mol Oncol"},{"issue":"7","key":"10267_CR51","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/neuonc\/noaa028","volume":"22","author":"J M\u00fcnsterberg","year":"2020","unstructured":"M\u00fcnsterberg J et al (2020) ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium. Neuro Oncol 22(7):955\u2013966","journal-title":"Neuro Oncol"},{"key":"10267_CR52","doi-asserted-by":"publisher","first-page":"43464","DOI":"10.1038\/srep43464","volume":"7","author":"WT Yan","year":"2017","unstructured":"Yan WT et al (2017) Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis. Sci Rep 7:43464","journal-title":"Sci Rep"},{"issue":"4","key":"10267_CR53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1515\/labmed-2022-0009","volume":"46","author":"C Keup","year":"2022","unstructured":"Keup C, Kimmig R, Kasimir-Bauer S (2022) Multimodality in liquid biopsy: does a combination uncover insights undetectable in individual blood analytes? J Lab Med 46(4):255\u2013264","journal-title":"J Lab Med"},{"issue":"1","key":"10267_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-019-1235-8","volume":"21","author":"D Fernandez-Garcia","year":"2019","unstructured":"Fernandez-Garcia D et al (2019) Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res 21(1):1\u201313","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10267_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-019-1229-6","volume":"21","author":"AA Davis","year":"2019","unstructured":"Davis AA et al (2019) Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. Breast Cancer Res 21(1):1\u20138","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10267_CR56","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-17-2092","volume":"24","author":"G Rossi","year":"2018","unstructured":"Rossi G et al (2018) Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer. Clin Cancer Res 24(3):560\u2013568","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10267_CR57","doi-asserted-by":"publisher","first-page":"611","DOI":"10.4149\/neo_2017_417","volume":"64","author":"W Wang","year":"2017","unstructured":"Wang W et al (2017) Plasma cell-free DNA integrity plus circulating tumor cells: a potential biomarker of no distant metastasis breast cancer. Neoplasma 64(4):611\u2013618","journal-title":"Neoplasma"},{"key":"10267_CR58","doi-asserted-by":"crossref","unstructured":"Liu HE et al (2020) Detection of EGFR mutations in cfDNA and CTCs, and comparison to Tumor tissue in Non-small-cell-lung-cancer (NSCLC) patients. Frontiers in Oncology, p 10","DOI":"10.3389\/fonc.2020.572895"},{"issue":"6","key":"10267_CR59","doi-asserted-by":"publisher","first-page":"a005819","DOI":"10.1101\/mcs.a005819","volume":"6","author":"L Welter","year":"2020","unstructured":"Welter L et al (2020) Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. Mol Case Stud 6(6):a005819","journal-title":"Mol Case Stud"},{"issue":"1","key":"10267_CR60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41523-022-00390-5","volume":"8","author":"SN Shishido","year":"2022","unstructured":"Shishido SN et al (2022) Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib. npj Breast Cancer 8(1):22","journal-title":"npj Breast Cancer"},{"issue":"5","key":"10267_CR61","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3390\/cancers12051084","volume":"12","author":"C Keup","year":"2020","unstructured":"Keup C et al (2020) Multimodal targeted deep sequencing of circulating Tumor cells and matched cell-free DNA provides a more Comprehensive Tool to identify therapeutic targets in metastatic breast Cancer patients. Cancers 12(5):1084","journal-title":"Cancers"},{"issue":"12","key":"10267_CR62","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/1878-0261.12540","volume":"13","author":"E Tzanikou","year":"2019","unstructured":"Tzanikou E et al (2019) PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. Mol Oncol 13(12):2515\u20132530","journal-title":"Mol Oncol"},{"issue":"1","key":"10267_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-021-00902-1","volume":"13","author":"C Keup","year":"2021","unstructured":"Keup C et al (2021) Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer. Genome Med 13(1):1\u201314","journal-title":"Genome Med"},{"issue":"11","key":"10267_CR64","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3390\/cancers11111656","volume":"11","author":"E Buscail","year":"2019","unstructured":"Buscail E et al (2019) High clinical value of Liquid Biopsy to detect circulating Tumor cells and Tumor exosomes in Pancreatic Ductal Adenocarcinoma patients Eligible for Up-Front surgery. Cancers 11(11):1656","journal-title":"Cancers"},{"key":"10267_CR65","doi-asserted-by":"crossref","unstructured":"Nanou A et al Tumor-derived extracellular vesicles as complementary prognostic factors to circulating Tumor cells in metastatic breast Cancer. JCO Precision Oncology, 2023(7): p. e2200372","DOI":"10.1200\/PO.22.00372"},{"issue":"5","key":"10267_CR66","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/1878-0261.12669","volume":"14","author":"S Schneegans","year":"2020","unstructured":"Schneegans S et al (2020) Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. Mol Oncol 14(5):1001\u20131015","journal-title":"Mol Oncol"},{"key":"10267_CR67","unstructured":"PANCAID Consortium. PANcreatic CAncer Initial Detection via liquid biopsy (PANCAID) (2023) [Accessed : 21 August 2023]; Available from: https:\/\/pancaid-project.eu"},{"issue":"9","key":"10267_CR68","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.molmed.2010.07.001","volume":"16","author":"K Pantel","year":"2010","unstructured":"Pantel K, Alix-Panabieres C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16(9):398\u2013406","journal-title":"Trends Mol Med"},{"key":"10267_CR69","doi-asserted-by":"crossref","unstructured":"Roeper CM et al (2023) \u201eLiquid biopsy \u2013schon reif f\u00fcr Therapieentscheidungen? best practice onkologie, : p. 1\u20139","DOI":"10.1007\/s11654-023-00484-x"},{"key":"10267_CR70","doi-asserted-by":"crossref","unstructured":"Koch C et al (2020) Pre-analytical and Analytical variables of label-independent Enrichment and Automated Detection of circulating Tumor cells in Cancer patients. Cancers (Basel), 12(2)","DOI":"10.3390\/cancers12020442"},{"issue":"4","key":"10267_CR71","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/clinchem\/hvaa322","volume":"67","author":"RPL Neves","year":"2021","unstructured":"Neves RPL et al (2021) Proficiency testing to assess Technical Performance for CTC-Processing and Detection methods in CANCER-ID. Clin Chem 67(4):631\u2013641","journal-title":"Clin Chem"},{"issue":"50","key":"10267_CR72","doi-asserted-by":"publisher","first-page":"87710","DOI":"10.18632\/oncotarget.21197","volume":"8","author":"Y Maertens","year":"2017","unstructured":"Maertens Y et al (2017) Comparison of isolation platforms for detection of circulating renal cell carcinoma cells. Oncotarget 8(50):87710\u201387717","journal-title":"Oncotarget"},{"key":"10267_CR73","unstructured":"European Liquid Biopsy Society. European Liquid Biopsy Society (ELBS) (2023) [Accessed : 21 August 2023]; Available from: www.elbs.eu"},{"issue":"1","key":"10267_CR74","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1373\/clinchem.2019.306837","volume":"66","author":"R Lampignano","year":"2020","unstructured":"Lampignano R et al (2020) Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre)analytical work flows. Clin Chem 66(1):149\u2013160","journal-title":"Clin Chem"},{"issue":"3","key":"10267_CR75","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ijc.33217","volume":"148","author":"I Heidrich","year":"2021","unstructured":"Heidrich I et al (2021) Liquid biopsies: potential and challenges. Int J Cancer 148(3):528\u2013545","journal-title":"Int J Cancer"},{"issue":"2","key":"10267_CR76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB et al (2017) The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin 67(2):93\u201399","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10267_CR77","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ccell.2017.01.002","volume":"31","author":"A Bardelli","year":"2017","unstructured":"Bardelli A, Pantel K (2017) Liquid biopsies, what we do not know (yet). Cancer Cell 31(2):172\u2013179","journal-title":"Cancer Cell"},{"issue":"8","key":"10267_CR78","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual J et al (2022) ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol 33(8):750\u2013768","journal-title":"Ann Oncol"},{"key":"10267_CR79","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.jlb.2023.100004","volume":"1","author":"P Hofman","year":"2023","unstructured":"Hofman P (2023) Implementation of the clinical practice of liquid biopsies for thoracic oncology the experience of the RespirERA university hospital institute (Nice, France). J Liquid Biopsy 1:100004","journal-title":"J Liquid Biopsy"},{"issue":"Suppl 8","key":"10267_CR80","doi-asserted-by":"publisher","first-page":"S354","DOI":"10.21037\/atm.2019.09.92","volume":"7","author":"A Rao","year":"2019","unstructured":"Rao A, Antonarakis ES (2019) Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility? Ann Transl Med 7(Suppl 8):S354","journal-title":"Ann Transl Med"},{"issue":"5","key":"10267_CR81","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis M, Sledge GW, Jeffrey SS (2021) Liquid biopsy enters the clinic \u2014 implementation issues and future challenges. Nat Reviews Clin Oncol 18(5):297\u2013312","journal-title":"Nat Reviews Clin Oncol"},{"key":"10267_CR82","unstructured":"Bidard F-C et al (2023) Overall survival with circulating Tumor Cell Count\u2013Driven choice of therapy in advanced breast Cancer: a Randomized Trial. J Clin Oncol, : p. JCO.23.00456."},{"issue":"1","key":"10267_CR83","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/clinchem\/hvad144","volume":"70","author":"T Fehm","year":"2024","unstructured":"Fehm T et al (2024) Efficacy of Lapatinib in patients with HER2-Negative metastatic breast Cancer and HER2-Positive circulating tumor cells\u2014the DETECT III Clinical Trial. Clin Chem 70(1):307\u2013318","journal-title":"Clin Chem"},{"issue":"3","key":"10267_CR84","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/clinchem\/48.3.421","volume":"48","author":"YY Lui","year":"2002","unstructured":"Lui YY et al (2002) Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 48(3):421\u2013427","journal-title":"Clin Chem"},{"key":"10267_CR85","unstructured":"GUIDE.MRD Consortium. Guiding multi-modal therapies against MRD by liquid biopsies (2023) [Accessed : 21 August 2023]; Available from: https:\/\/www.guidemrd-horizon.eu"},{"key":"10267_CR86","doi-asserted-by":"publisher","first-page":"S276","DOI":"10.1016\/j.annonc.2023.09.2960","volume":"34","author":"K Pantel","year":"2023","unstructured":"Pantel K et al (2023) 237TiP GUIDE.MRD: a Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to improve patient outcomes. Ann Oncol 34:S276\u2013S277","journal-title":"Ann Oncol"},{"key":"10267_CR87","doi-asserted-by":"publisher","first-page":"103112","DOI":"10.1016\/j.critrevonc.2020.103112","volume":"156","author":"D Connors","year":"2020","unstructured":"Connors D et al (2020) International liquid biopsy standardization alliance white paper. Crit Rev Oncol Hematol 156:103112","journal-title":"Crit Rev Oncol Hematol"},{"key":"10267_CR88","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejca.2022.11.039","volume":"180","author":"AKM Jakobsen","year":"2023","unstructured":"Jakobsen AKM, Spindler KG (2023) ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology. Eur J Cancer 180:180\u2013183","journal-title":"Eur J Cancer"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10267-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-024-10267-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10267-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T15:14:45Z","timestamp":1725462885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-024-10267-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,28]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10267"],"URL":"https:\/\/doi.org\/10.1007\/s10585-024-10267-5","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,28]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.P. received honoraria outside of this work from NRich, BMS, Agena, Menarini, Novartis, Sanofi, Illumina, Abcam, MSD, Eppendorf and Hummingbird.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}